title: Estradiol valerate/dienogest: in oral contraception.
abstract: Estradiol valerate/dienogest is an oral contraceptive for women that combines the natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic formulation. Estradiol valerate/dienogest demonstrated contraceptive efficacy in a large (n = 1377), noncomparative, multicentre study in women aged 18-50 years, with 13 pregnancies over 1797.5 women-years of exposure generating an unadjusted Pearl Index (PI) of 0.73 (upper limit of 95% CI 1.24) [primary endpoint]. Six of the pregnancies were attributed to method failure, resulting in an adjusted PI, based on 1786.5 women-years of exposure, of 0.34 (upper limit of 95% CI 0.73). In a double-blind study in 798 women aged 18-50 years, estradiol valerate/dienogest and ethinylestradiol/levonorgestrel demonstrated an acceptable bleeding pattern and level of cycle control, according to several co-primary endpoints. As reported in the UK manufacturer's summary of product characteristics, the unadjusted PI for women aged 18-35 years or 18-50 years in a pooled analysis of clinical studies was 1.01 (upper limit of 95% CI 1.59) and 0.79 (upper limit of 95% CI 1.23). This pooled analysis of three studies excluded those pregnancies occurring within 14 days of the cessation of therapy. Estradiol valerate/dienogest was generally well tolerated in this population, with the nature of adverse events generally similar across the studies and between estradiol valerate/dienogest and ethinylestradiol/levonorgestrel.
authors.affiliation: Wolters Kluwer Health/Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Sheridan M
authors.initials: SM
authors.lastname: Hoy
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Scott
mesh_terms: D000293:Adolescent; D000328:Adult; D002626:Chemistry, Pharmaceutical; D003276:Contraceptives, Oral / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009277:Nandrolone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D011247:Pregnancy; D055815:Young Adult
chemical_list: D003276:Contraceptives, Oral; D004338:Drug Combinations; C023635:dienogest; D004958:Estradiol; D009277:Nandrolone
references.citation: Eur J Contracept Reprod Health Care. 2009 Jun;14(3):221-32
references.pmid: 19565420
references.citation: Contraception. 1993 Jun;47(6):583-90
references.pmid: 8334892
references.citation: BJOG. 2009 Jan;116(2):230-9
references.pmid: 19076955
references.citation: Contraception. 2008 Sep;78(3):218-25
references.pmid: 18692612
references.citation: Drugs. 2002;62(3):491-504; discussion 505-6
references.pmid: 11827562
references.citation: Contraception. 2009 Nov;80(5):436-44
references.pmid: 19835717